INTRODUCTION

Pulmonary arterial hypertension (PAH) is a progressive disease that is often fatal. PAH occurs when the pulmonary circulation pressure is higher than normal, a condition caused by diseases (such as heart or lung disease and lung artery disease), hereditary factors and a variety of pathogens. The clinical characteristic is that pulmonary vascular resistance progressively increases, which obstructs the right ventricular ejection, leading to right heart failure and even death. PAH is an important pathophysiological link that occurs during the development of many heart and lung diseases. Once it occurs, it seriously affects the progress and
prognosis of primary cardiopulmonary disease, thus making it a key global health issue. PAH used to be considered a disease occurring mainly in young people. However, further research has found that the prevalence and mortality of PAH are on the rise in the elderly population. The pathogenesis of PAH is closely related to heart and pulmonary circulation. PAH etiology, clinical characteristics and treatment in the elderly are very different from those for younger patients, largely due to aging as the heart and lung function decline. In fact, elderly patients with PAH are often admitted to the intensive care unit (ICU) for treatment because of the disease’s progression and right ventricular dysfunction. Unfortunately, there is currently no research about the prevalence, risk factors and outcomes in critically ill elderly patients with PAH. Right heart catheterization is the gold standard for PAH diagnosis, but the examination is an invasive procedure, especially for elderly patients with poor adherence, and is not suitable for promotion as a clinical screening.

In 2009, the European Society of Cardiology (ESC) released its PAH diagnosis and treatment guidelines, which clearly stated that transthoracic Doppler echocardiography is a good non-invasive screening method for PAH. We observed critically ill elderly patients for this study. We used color Doppler ultrasound for the preliminarily screening of the PAH patients; we then collected clinical data and investigated the prevalence, prognosis and possible potential risk factors of PAH. We provide evidence in this paper for the prevention and treatment of critically ill elderly patients with PAH.

METHODS

Subjects: In this study, a total of 122 elderly patients were included from January 2014 to March 2015; these patients had been admitted to the geriatric ICU, comprehensive ICU, emergency ICU and respiratory ICU of Jiangsu Provincial Hospital. There were 78 male patients and 44 female patients; their ages ranged from 60–93 years old, with an average age of 74.4 (± 8.0) years old. All the patients met the criteria for admission into the ICUs according to the Intensive Medicine and Constructive Management Guide, 2009 Edition. This study was approved by the ethics committee of Jiangsu Province Hospital with the reference number: 2016-SR-148.

Methods: We performed an echocardiography examination on each patient within the first four days of their ICU admission. In addition to the conventional measurement of the diameters of the four heart cavities, we recorded, in detail, the related echocardiography data (i.e., the pulmonary artery systolic pressure (PASP) and left ventricular ejection fraction (EF), as well as the indicators reflecting the systolic and diastolic function of the right and left ventricles). We collected clinical data, routine laboratory data and a detailed record of each patient’s medical history, including their use of medication. We recorded their lipids, N-terminal pro-brain natriuretic peptides, total bilirubin, uric acid and high-sensitivity C-reactive protein. We recorded each patient’s prognosis and outcome, as well as any treatments provided to the patient during the ICU stay, including the use of mechanical ventilation and vasoactive drugs. Patients were divided into a normal pulmonary arterial pressure group and a PAH group in accordance with the internationally recommended standard for PAH diagnosis by echocardiography (PASP ≥ 40 mmHg). Our statistics for the PAH group were categorized according to WHO classification criteria based on the patient’s medical history and test data. Statistical methods were used to compare the differences in the clinical data for issues such as cardiac ultrasound data and the laboratory data between the two groups. We used 30-day mortality and length of stay in ICU as the main outcome variable and analyzed the risk factors for PAH occurrence in critically ill elderly patients. In addition, all cases were grouped according to the 30-day mortality, and we used single factor and multivariate regression analysis to analyze the impact of the patient’s primary disease and PAH on the prognosis.

Statistical Methods: We used SPSS 21.0 software for all statistical analysis; χ² test was used for categorical data, and numerical data were presented as X ± s and analyzed with t test. Logistic regression analysis was used. P < 0.05 was considered statistically significant.

RESULTS

Clinical Data Analysis: Using the estimated PASP data, 122 cases were divided into two groups: a normal pulmonary artery pressure group and the PAH group. The PAH group contained 51 cases (41.8%) and the average PASP was 51.5 ± 12.9 mmHg; when this average was compared to the normal pulmonary group, the difference was found to be statistically significant (P < 0.0001). Based on the patients’ history and test data, 17 cases (33.3%) were categorized as Group 2 (that is, they suffered from pulmonary hypertension caused by left heart disease) and 26 cases (51.0%) were categorized as Group 3.
Pulmonary hypertension in critically ill elderly patients

Table-I: Age, sex, current illness, outcome variable and other clinical indicators of the two groups.

| Pulmonary arterial hypertension group | Normal pulmonary artery pressure group | χ²   | P     |
|---------------------------------------|---------------------------------------|------|-------|
| Number of cases                       | 51 (41.8%)                           | 71 (58.2%) |      |       |
| PASP (mmHg)                           | 51.5 ± 12.9                           | 30.4 ± 5.4 | <0.0001 |       |
| Age (years)                           | 73.9 ± 8.4                            | 74.8 ± 7.8 | 0.462  |       |
| Sex (male)                            | 28 (54.9%)                            | 50 (70.4%) | 3.101  | 0.078 |
| Hypertension (cases)                  | 24 (47.1%)                            | 36 (50.7%) | 0.158  | 0.691 |
| Diabetes (cases)                      | 11 (21.6%)                            | 20 (28.2%) | 0.682  | 0.409 |
| COPD (cases)                          | 19 (37.3%)                            | 14 (19.7%) | 4.626  | 0.031 |
| Septic shock (cases)                  | 17 (33.3%)                            | 25 (35.2%) | 0.046  | 0.83  |
| Cardiac-related coronary heart disease (cases) | 11 (21.6%)                            | 22 (30.9%) | 1.334  | 0.248 |
| Lung infection (cases)                | 25 (49.0%)                            | 36 (50.7%) | 0.034  | 0.854 |
| Respiratory failure (cases)           | 24 (47.1%)                            | 19 (26.8%) | 5.358  | 0.021 |
| Cerebrovascular diseases (cases)      | 5 (9.8%)                              | 9 (12.7%)  | 0.241  | 0.623 |
| Digestive system related (cases)      | 5 (9.8%)                              | 10 (14.1%) | 0.504  | 0.478 |
| Renal failure (cases)                 | 6 (11.8%)                             | 7 (9.9%)   | 0.113  | 0.737 |
| Length of stay in ICU (days)          | 17.0 ± 14.6                           | 13.8 ± 9.4 |       | 0.090 |
| 30-day mortality (cases)              | 17 (33.3%)                            | 12 (16.9%) | 4.423  | 0.035 |

Table-II: Ultrasound data and some laboratory data of the two groups.

| Pulmonary arterial hypertension group | Normal pulmonary artery pressure group | t     | P     |
|---------------------------------------|---------------------------------------|------|-------|
| Number of cases                       | 51 (41.8%)                           | 71 (58.2%) |      |       |
| EF (%)                                | 61.9 ± 7.5                           | 60.8 ± 7.2 | 0.685 | 0.99  |
| LAD (mm)                              | 40.0 ± 9.9                           | 37.6 ± 7.2 | 1.53  | 0.038 |
| LVDD (mm)                             | 47.5 ± 7.6                           | 47.3 ± 6.7 | 0.054 | 0.298 |
| LVDs (mm)                             | 32.2 ± 6.4                           | 31.4 ± 5.9 | 0.392 | 0.448 |
| LVPW (mm)                             | 9.8 ± 1.1                            | 10.4 ± 1.3 | −2.006| 0.078 |
| IVS (mm)                              | 10.2 ± 1.3                           | 10.6 ± 1.6 | −1.535| 0.097 |
| FS (%)                                | 32.9 ± 6.9                           | 33.4 ± 4.0 | −0.456| 0.038 |
| RVDD (mm)                             | 41.5 ± 7.1                           | 31.8 ± 4.2 | 2.801 | 0.029 |
| NT-proBNP (pg/ml)                     | 4279.25 ± 7505.48                    | 2483.26 ± 5423.29 | 1.519 | 0.046 |
| Uric acid (μmol/l)                    | 270.32 ± 164.19                      | 254.29 ± 143.54 | 1.329 | 0.06  |
| Hypersensitive CRP (mg/L)             | 66.17 ± 70.72                        | 85.43 ± 101.23 | −0.774| 0.455 |
| Total bilirubin (μmol/L)              | 16.67 ± 26.19                        | 16.13 ± 18.73 | 0.837 | 0.090 |

Note: EF: Ejection fraction; LAD: Left atrial diameter; LVDD: Diastolic left ventricular diameter; LVDs: Systolic left ventricular diameter; LVPW: Left ventricular wall thickness; FS: (LV) Fractional shortening rate; RVDD: Right ventricular end-diastolic diameter; NT-proBNP: N-terminal pro-brain natriuretic peptide; CRP: C-reactive protein.

(they suffered from pulmonary hypertension due to chronic hypoxic disease); these data were classified according to the revised diagnostic classification criteria released from the WHO Fifth World Symposium on Pulmonary Hypertension held in Nice, France, in 2013. The remaining 8 cases could not be clearly classified according to the existing data. The PAH group was compared with the normal pulmonary artery pressure group based on clinical indicators such as age, sex, current illness, length of stay in ICU, 30-day mortality and echocardiographic data, as well as part of the laboratory data (Tables-I and II). The results showed that COPD and/or respiratory failure were more likely to co-exist with PAH ($\chi^2 = 4.626, P = 0.031; \chi^2 = 5.358, P = 0.021$). The 30-day mortality was 33.3% for the PAH group, which was higher than that for the normal pulmonary artery pressure group ($\chi^2 = 4.423, P = 0.035$). The diameter of the left ventricle, the right ventricular end-diastolic diameter and the amount of N-terminal pro-brain natriuretic peptides for the PAH group were higher than those found in the normal pulmonary artery group ($t = 1.53, P = 0.038; t = 2.801, P = 0.029; t = 1.519, P = 0.046$), while the LV...
fractional shortening rate was lower for the latter group ($t = -0.456, P = 0.038$).

**Multivariate Regression Analysis:** We used logistic regression analysis for the statistically significant indicators obtained by univariate analysis between the normal pulmonary artery pressure group and the PAH group. When controlling for these clinical features, enlarged left atrium and right ventricle remained independently associated with PAH in critically ill elderly patients ($OR = 0.806, 95\% CI: 0.646–1.005, P = 0.045; OR = 0.735, 95\% CI: 0.559–0.966, P = 0.027$) (Table-III).

**Analysis of Risk Factors for 30-day mortality:** All cases were grouped based on 30-day mortality (Table-IV); the indexes were compared between the two groups, such as age, sex, current illness and whether the patient was provided with mechanical ventilation and/or vasoactive drugs when admitted to the ICU. The results of the logistic regression analysis showed that when critically ill elderly patients were admitted to the ICU, those who suffered from PAH, required the use of mechanical ventilation, or had an unstable blood pressure that needed vasoactive drug support were at an increased risk of mortality ($OR = 2.513, 95\% CI: 1.045–6.041, P = 0.039; OR = 3.479, 95\% CI: 1.345–9.000, P = 0.010; OR = 3.226, 95\% CI: 1.353–7.691, P = 0.008$, respectively) (Table-V).

**DISCUSSION**

There are still many problems with treating those suffering from PAH due to the complexity of the disease and a lack of understanding of the pathogenesis of PAH. The typical patient’s prognosis remains poor and treatment options are limited, which poses a significant threat to the overall patient care. PAH patients require better treatment methods that incorporate all of the clinical

| Table-III: Multivariate regression analysis of risk factors in critically ill elderly patients with pulmonary arterial hypertension. |
| --- |
| **Factors** | **B** | **SE** | **Wald χ²** | **P** | **OR** | **95\% CI** |
| COPD | 0.220 | 1.264 | 0.030 | 0.862 | 1.246 | 0.105–14.836 |
| Respiratory failure | -0.760 | 1.148 | 0.438 | 0.508 | 0.468 | 0.049–4.439 |
| RVDD (mm) | -0.308 | 0.139 | 4.874 | 0.027 | 0.735 | 0.559–0.966 |
| LAD (mm) | -0.216 | 0.113 | 3.675 | 0.045 | 0.806 | 0.646–1.005 |
| FS (%) | -0.346 | 0.201 | 2.970 | 0.085 | 0.707 | 0.477–1.049 |
| NT-proBNP (pg/ml) | 0.000 | 0.001 | 0.454 | 0.500 | 1.000 | 0.998–1.001 |

| Table-IV: Age, sex, current illness and other clinical indicators of the two groups. |
| --- |
| **Death group** | **Survival group** | **χ²** | **P** |
| Number of cases | 29 (23.8%) | 93 (76.2%) | |
| Age (years of old) | 76.24 ± 8.09 | 73.73 ± 7.87 | 0.12 |
| Sex (male) | 18 (62.1%) | 60 (64.5%) | 0.057 | 0.811 |
| PAH (cases) | 17 (58.6%) | 34 (36.6%) | 4.423 | 0.035 |
| Lung infection (cases) | 15 (51.7%) | 46 (49.5%) | 0.045 | 0.832 |
| Hypertension (cases) | 16 (55.2%) | 44 (47.3%) | 0.547 | 0.46 |
| Cardiac-related Coronary heart disease (cases) | 8 (27.6%) | 25 (26.9%) | 0.006 | 0.941 |
| COPD (cases) | 9 (31.0%) | 24 (25.8%) | 0.306 | 0.58 |
| Diabetes (cases) | 6 (20.7%) | 25 (26.9%) | 0.447 | 0.504 |
| Cerebrovascular diseases (cases) | 3 (10.3%) | 11 (11.8%) | 0.048 | 0.827 |
| Digestive System Related (cases) | 3 (10.3%) | 12 (12.9%) | 0.134 | 0.714 |
| Renal failure (cases) | 4 (13.8%) | 9 (9.7%) | 0.641 | 0.423 |
| Whether mechanical ventilation used (cases) | 16 (55.2%) | 24 (25.8%) | 8.651 | 0.003 |
| Whether vasoactive drugs used (cases) | 17 (58.6%) | 25 (26.9%) | 9.865 | 0.002 |

| Table-V: Multivariate regression analysis: Mortality of critically ill elderly patients in the ICU. |
| --- |
| **Factors** | **B** | **SE** | **Wald χ²** | **P** | **OR** | **95\% CI** |
| Pulmonary arterial hypertension | 0.922 | 0.448 | 4.24 | 0.039 | 2.513 | 1.045–6.041 |
| Mechanical ventilation | 1.247 | 0.485 | 6.61 | 0.01 | 3.479 | 1.345–9.000 |
| Vasoactive drugs | 1.171 | 0.443 | 6.979 | 0.008 | 3.226 | 1.353–7.691 |
Pulmonary hypertension in critically ill elderly patients

characteristics of the elderly patients. Because of the special physiological mechanisms at work in the elderly, the harm from PAH is far greater for this population than that for younger people. RAVEAL research findings from a multi-center study found that male patients with PAH who were over 60 years of age had a higher mortality rate than those under 60 years of age.7 COMPERA found that the 1-, 2- and 3-year survival rates of elderly patients with a primary diagnosis of PAH were even lower than those in younger patients.8 However, there is still a lack of studies on the incidence of PAH, especially for critically ill elderly patients. The results of this study showed that the incidence of PAH in critically ill elderly patients is 41.8%, while studies from Cao9 and Rich10 reported that the incidence of PAH in elderly patients in general wards were 10.5% and 28.2%, respectively. Our data proved that elderly patients in the ICU had a significantly higher incidence of PAH than those in the general ward. This finding deserves more attention. Studies have found that the most common type of PAH in the elderly is the type associated with left heart diseases, particularly left atrial or ventricular heart disease.4 Grigioni et al.13 analyzed 196 cases of patients with class III-IV heart failure; after they adjusted for the clinical and laboratory examinations and other indicators, they found that PAH is an independent predictor of acute heart failure and cardiac death. Our data suggested that among the critically ill elderly patients admitted to the ICU, one-third of those with left ventricle diseases had PAH, while PAH caused by a chronic hypoxic pulmonary disease (such as COPD) were still the largest fraction (they accounted for half of the cases). This differs with the data from the general ward. Some studies showed that regardless the severity of PAH, the survival rate is low if COPD is the cause.12 In fact, if PAH progresses, it usually leads to an increase in the right heart load, resulting in right ventricular failure; this insight requires that healthcare providers pay more attention to the right ventricular function in critically ill elderly patients.

Our results showed that in PAH, the pulmonary circulation pressure in the early stages was already higher than that found in other types of PAH patients, which is consistent with the results of this study. Taking into account the variety of diseases often associated with ICU patients, we put factors such as current illness and the use of mechanical ventilation and vasoactive drugs upon admittance to the ICU into the multivariate regression analysis to determine the mortality rate. Our results showed that, when admitted to the ICU, patients with other diseases and PAH have an independent risk factor for increased mortality. The presence of respiratory failure and shock in critically ill patients, who often need mechanical ventilation and vasoactive drug treatment, suggests a poor prognosis for them. Huynh et al.’s study indicated that if PAH
patients received CPR, their mortality rate was 100%. Mortality also increased if hemodialysis and mechanical ventilation were needed. At present, there are few studies regarding the outcome and prognosis of PAH patients in the ICU. A follow-up study is needed to confirm whether PAH interventions can improve a patient’s prognosis.

In summary, a higher incidence of PAH occurs in critically ill elderly patients; an enlarged left atrium is the risk factor for PAH in this group. There is some association between the left ventricular diastolic function and occurrence/development of PAH for this elderly population, as well. PAH is an independent risk factor for increased mortality in critically ill elderly patients. Present, further study is required to expand the sample size and study the pathogenesis and treatment interventions in order to improve the prognosis for those who suffer from PAH.

ACKNOWLEDGEMENT

This work was supported by the Cadre Healthcare Research Fund from Jiangsu Province Commission of Health and Family Planning (BJ14001).

Declaration of conflict of interest: None.

REFERENCES

1. Tuder RM, Abman SH, Braun T, Capron F, Stevens T, Thistlethwaite PA, et al. Development and pathology of pulmonary hypertension. J Am Coll Cardiol. 2009;54(Suppl 1):S3-9. doi: 10.1016/j.jacc.2009.04.009.
2. Zhicheng J, Xiqi X. The road to treat pulmonary hypertension, hard and promising. Chin J Intern Med. 2013;52(8):628-630. doi: 10.3760/cma.j.issn.0578-1426.2013.08.002.
3. McArdle JR, Trow TK, Lerz K. Pulmonary hypertension in older adults. Clin Chest Med. 2007;28(4):717-733. doi: 10.1016/j.ccm.2007.08.006.
4. Pugh ME, Sivarajan L, Wang L, Robbins IM, Newman JH, Hennes AR. Causes of pulmonary hypertension in the elderly. Chest. 2014;146(1):159-166. doi: 10.1378/ chest.13-1900.
5. Badesch DB, Champion HC, Sanchez MA, Hooper MM, Loyd JE, Manes A, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(Suppl 1):S55-66. doi: 10.1016/j.jacc.2009.04.011.
6. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53(17):1573-1619. doi: 10.1016/j. jacc.2009.01.004.

7. Shapiro S, Traiger GL, Turner M, McGoon MD, Wason P, Barst RJ. Sex differences in the diagnosis, treatment, and outcome of patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Chest. 2012;141(2):363-373. doi: 10.1378/chest.10-3114.
8. Hoeper MM, Huscher D, Ghofrani HA, Delcroix M, Distler O, Schweiger C, et al. Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol. 2013;168(2):871-880. doi: 10.1016/j.ijcard.2012.10.026.
9. Jian C, Lin L, Jian L, Bipn ZH, Yu D, Hao W, et al. The prevalence and risk factors for pulmonary hypertension diagnosed by echocardiogram in the elderly hospitalized patients. Chinese J Geriatrics. 2012;31(1):57-60. doi: 10.3760/ cma.j.issn.0254-9026.2012.01.019.
10. Rich S, Chomka E, Hasara L, Hart K, Drizd T, Joo E, et al. The prevalence of pulmonary hypertension in the United States. Adult population estimates obtained from measurements of chest roentgenograms from the NHANES II Survey. Chest. 1989;96(2):236-241.
11. Grigioni F, Potena L, Galie N, Fallani F, Bigliardi M, Coccoto F, et al. Prognostic implications of serial assessments of pulmonary hypertension in severe chronic heart failure. J Heart Lung Transplant. 2006;25(10):1241-1246. doi: 10.1016/j.healun.2006.06.015.
12. Weitzenblum E, Hirth C, Ducolone A, Mirhom R, Rasaholinjanahary E, Ihrhart M. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax. 1981;36(10):752-758.
13. Paulus WJ, Tschöpe C, Sanderson JE, Rusconi C, FlachskaMF, Rademakers FE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007;28(21):2539-2550. doi: 10.1093/eurheartj/ ehm037.
14. Vonk Noordegraaf A, Galie N. The role of the right ventricle in pulmonary arterial hypertension. Euro Respir Rev. 2011;20:243-253. doi: 10.1183/09059180.00006511.
15. Huynh TN, Weigt SS, Sugar CA, Shapiro S, Kleerup EC. Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;54(Suppl 1):S55-66. doi: 10.1016/j.jacc.2009.10.026.
16. Cortez TJ, Wurt S, Gatzoulis MA, Macdonald P, Hansell DM, Wells AU. Pulmonary vascular resistance predicts early mortality in patients with diffuse fibrotic lung disease and suspected pulmonary hypertension. Thorax. 2009;64(10):883-888. doi: 10.1136/thx.2008.112847.

Authors’ Contributions:

YYZ: Conceived, designed and did statistical analysis & writing of manuscript.
FX and MC: Did data collection and editing of manuscript.
LQB: Did review and final approval of manuscript.